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Background: Edaravone (EDR) is known for its free radical scavenging, antiapoptotic, 
antinecrotic, and anticytokine effects in neurological and non-neurological diseases. It is currently 
available clinically as Radicava® and Radicut®, intravenous medications, recently approved for 
the treatment of amyotrophic lateral sclerosis and cerebral infarction. However, the oral use 
of EDR is still restricted by its poor oral bioavailability (BA) due to poor aqueous solubility, 
stability, rapid metabolism, and low permeability. The present study reports the development of 
novel EDR formulation (NEF) using self-nanomicellizing solid dispersion (SNMSD) strategy 
with the aim to enable its oral use.
Materials and methods: The selection of a suitable carrier for the development of NEF 
was performed based on the miscibility study. The optimization of EDR-to-carrier ratio was 
conducted via kinetic solubility study after preparing SNMSDs using solvent evaporation 
technique. The drug–polymer carrier interaction and self-nanomicellizing properties of NEF 
were investigated with advanced characterization studies. In vitro permeation, metabolism, and 
dissolution study was carried out to examine the effect of the presence of a carrier on physico-
chemical properties of EDR. Additionally, the dose-dependent pharmacokinetic study of NEF 
was conducted and compared with the EDR suspension.
Results: Soluplus® (SOL) as a carrier was selected based on the potential for improving aque-
ous solubility. The NEF containing EDR and SOL (1:5) resulted in the highest enhancement 
in aqueous solubility (17.53-fold) due to amorphization, hydrogen bonding interaction, and 
micellization. Moreover, the NEF demonstrated significant improvement in metabolism, perme-
ability, and dissolution profile of EDR. Furthermore, the oral BA of NEF showed 10.2-, 16.1-, 
and 14.8-fold enhancement compared to EDR suspension at 46, 138, and 414 µmol/kg doses.
Conclusion: The results demonstrated that SNMSD strategy could serve as a promising way 
to enhance EDR oral BA and NEF could be a potential candidate for the treatment of diseases 
in which oxidative stress plays a key role in their pathogenesis.
Keywords: edaravone, Soluplus®, nanotechnology, oral bioavailability, metabolism, 
permeability
Introduction
Edaravone (EDR) is a well-established potent antioxidant and strong free radical 
scavenging drug, particularly in Japan since 2001 after receiving approval for acute 
ischemic stroke.1,2 Recently, it garnered global attention for gaining approval in the 
United States and Japan for amyotrophic lateral sclerosis (ALS) in years 2017 and 2015, 
respectively.3 Chemically, it is 3-methyl-1-phenyl-2-pyrazolin-5-one and belongs to 
the therapeutic class of central nervous system agents.4 The therapeutic activity of 
EDR is due to the removal of hydroxyl radical, modulation of inflammatory processes 
as well as neurodegenerative processes, apoptotic and necrotic cell death, nitric oxide 
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production, and matrix metalloproteinase levels.1,2 The 
unique feature of EDR is access to the brain through blood–
brain barrier due to its high lipophilicity and low molecular 
weight (174.203 g/mol); thus, its activity is not limited to 
vascular compartment.5 Its therapeutic potential against both 
neurological and non-neurological diseases was already 
proven from several in vitro and in vivo experiments includ-
ing stroke,5–7 Alzheimer’s disease,8,9 epilepsy,10 pneumo-
coccal meningitis,11 motor neuron disease,7,12,13 spinal cord 
injury,14 myocardial injury,15 liver injury,16 renal injury,17,18 
lung injury,19 cardiac fibrosis and dysfunction,20 chronic 
nephropathy,18 and retinal diseases.21
The oral route of administration is the most preferred by 
patients considering their compliance and comfort. Accurate 
and flexible dosing, easy production, economic, and higher 
stability are the key reasons for most frequent use of oral 
route for drug administration.22 EDR was proved to be orally 
active against the Alzheimer’s disease8 and cerebral aneu-
rysms.23 Moreover, Treeway, a biotech company, developed 
an unrevealed oral formulation of EDR to conduct clinical 
trials for ALS, which received orphan designation from 
regulatory agencies including European Medicines Agency 
(2014)24 and US Food and Drug Administration (USFDA) 
(2015).25 However, the current approved and available forms 
of EDR in the market are Radicava® and Radicut® (Mitsubishi 
Tanabe Pharmaceuticals, Osaka, Japan), the intravenous 
infusion solutions for parenteral administration. Rong et al26 
reported the poor absolute oral bioavailability (BA) (5.23%) 
of EDR. Besides, it was designated as class IV drug as per 
Biopharmaceutics Classification System (BCS) due to its 
poor aqueous solubility (1.85±0.15 mg/mL) and permeability 
(Peff =3.18±0.0706×10−7 cm/s).26,27 EDR is recognized as a 
substrate of P-glycoprotein (Pgp). Thus, despite being highly 
lipophilic in nature, poor intestinal permeability was reported 
with EDR. Pgp plays a major role in limiting drug absorption 
by enhancing Pgp-mediated efflux and consequently reducing 
the oral BA of EDR.26 The poor oral BA was the key reason 
for the failure of a clinical trial of potential candidates against 
alzheimer disease such as curcumin.28,29 Therefore, there is a 
need to conduct the clinical trials for its safety and efficacy 
study at large scale for the development of EDR as a thera-
peutic for the treatment of diseases in which oxidative stress 
plays a key role in their pathogenesis. To improve the oral 
BA of EDR, the complexation of EDR with hydroxypropyl-
sulfobutyl-β-cyclodextrin showed promising results by dis-
playing a 10.3-fold improvement by improving its solubility, 
dissolution, and permeability.26 However, the impact on 
aqueous stability as well as rapid metabolism was not studied. 
Furthermore, its commercial translation was not realized pos-
sibly due to the high molecular weight of cyclodextrin, the 
slow process of complexation, and the unstable condition of 
processing media.30 Besides, the novel oral delivery system of 
EDR based on co-solvency and pH modification technology 
showed limited success by improving oral BA by 5.71-fold.27 
Based on this, the liquid and solid lipid-based nanosystem 
(LNS) of EDR revealed 10.79- and 9.29-fold improvement in 
oral BA of EDR compared to EDR suspension, respectively, 
due to significant improvement in solubility, modulation of 
Pgp efflux pump, and inhibition of uridine 5-diphospho-
glucuronosyl-transferase (UGT) enzymes.31 However, solid 
dispersion-based formulation showed improvement in solubil-
ity, stability, and BA compared to lipid-based formulations in 
case of clopidogrel napadisilate.32 Also, the issues associated 
specifically with self-microemulsifying drug delivery system 
could restrict its chronic use including high surfactant concen-
tration, which causes gastrointestinal irritation and chemical 
instabilities of drugs.33 Hence, a novel oral formulation of 
EDR is necessary to offer a superior oral BA compared to 
currently available alternatives, suitability for chronic use, and 
have commercialization potential. Self-nanomicellizing solid 
dispersion (SNMSD) is the combination of widely accepted 
solid dispersions and nanomicelles’ strategies to improve the 
oral BA of challenging drugs. The dramatic improvement 
in oral BA of drugs including curcumin34,35 and ritonavir,36 
belonging to BCS class IV using SNMSD strategy by improv-
ing solubility, stability, and intestinal permeability.27,31 Use 
of SNMSD strategy to enhance the oral BA of EDR is yet 
to be studied as per our knowledge. Thus, it was explored to 
develop novel EDR formulation (NEF). The work reported 
here aimed to develop NEF using the SNMSD strategy and 




EDR was purchased from Aladdin Industrial Corporation 
(Shanghai, China). Soluplus® (SOL) and CAVASOL® W7 HP 
PHARMA (hydroxypropyl-β-cyclodextrin [HP-β-CD]) were 
gifted by BASF Australia Ltd (Melbourne, VIC, Australia) 
and Chemiplas Australia Pty Ltd (Melbourne, VIC, Australia), 
respectively. Potassium pyrophosphate, Tyrode’s solution, 
ascorbic acid, sodium carboxymethylcellulose, polyvinylpyr-
rolidone K 30 (PVP K30), polyethylene glycol (PEG) 4000, 
poloxamer 188, poloxamer 407, concentrated hydrochloric 
acid, perchloric acid, formic acid, disodium hydrogen 
phosphate, citric acid, uridine diphosphate glucuronic acid 
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(UDPGA) trisodium salt, alamethicin, d-glucaric acid 1,4-
lactone, and DMSO-d
3
 were purchased from Sigma-Aldrich 
Co. (St Louis, MO, USA). Acetic acid, phosphoric acid, 
sucrose, magnesium chloride, and sodium hydroxide pellets 
were obtained from Chem-Supply (Gillman, SA, Australia), 
boric acid was obtained from Optigen Scientific (Port Ade-
laide, SA, Australia), saline was obtained from Pfizer, Inc. 
(New York, NY, USA), and Pierce BCA Protein Assay Kit 
was obtained from Thermo Fisher Scientific (Waltham, MA, 
USA). High-performance liquid chromatography (HPLC) 
grade ethanol and methanol were purchased from EMD 
Millipore (Billerica, MA, USA). High-purity water using a 
Milli-Q water purification system (Millipore Ultrapure Water 
System; EMD Millipore) was used throughout the study. All 
other reagents were of analytical grade.
Formulation development and 
optimization of neF
selection of a suitable carrier for the development 
of neF
The carrier selection was performed based on the miscibility 
study as described previously.37 The solutions of polymeric 
carriers including SOL, HP-β-CD, PVP K30, PEG 4000, 
poloxamer 407, and poloxamer 188 were prepared at differ-
ent concentrations including 2.5, 5, 7.5, and 10% (w/v) using 
water. An excess amount of EDR was added to each polymeric 
solution in glass vials and allowed to shake in a mechanical 
shaker (Axyos Technologies, Brisbane, QLD, Australia) for 
24 h with 150 rpm at ambient temperature.27 Subsequently, 
each sample was filtered through 0.45 µm polyvinyl difluoride 
(PVDF) syringe filter and diluted with appropriate dilution by 
mobile phase. For the assay of EDR, the analytical method 
from the Japanese Pharmacopeia was used as per the previous 
study with minor modification.75 The analysis of samples was 
conducted using the ultraviolet (UV)–visible spectrophotom-
eter detector – HPLC method with a mobile phase consisting 
of water, methanol, and acetic acid (100:100:1) with 1 mL/
min flow rate and 20 µL injection volume at 240 nm.27
Preparation of snMsD using solvent evaporation 
(se) technique
SE method was used to prepare the SNMSDs of EDR and 
SOL, a selected polymer from miscibility study, as described 
by Wang et al.38 EDR and SOL at the ratio of 1:1, 1:2.5, 
1:5, 1:7.5, 1:10, 1:12.5, and 1:15 were dissolved in ethanol. 
Subsequently, the mixture was allowed to evaporate under 
the vacuum (500–600 mbar) using a rotatory evaporator at 
55°C–60°C. SNMSDs were then scraped using a spatula, 
pulverized in the mortar-pestle and passed through 250 µm 
sieve. All prepared SNMSDs were kept overnight in the 
desiccator for drying and stored in a refrigerator at 4°C until 
use for further studies.
Kinetic solubility study
The selection of SNMSD as a NEF was based on the kinetic 
solubility study. SNMSDs or EDR was added in an excess 
amount to 2 mL of simulated intestinal fluid (SIF), pH 6.8, in 
glass vials.39 The solubility study was conducted as described 
previously, and samples were collected at predetermined 
time intervals.27
characterization of neF
comparison of solubility of neF with unformulated 
eDr and physical mixture (PM)
To prepare PM, EDR and SOL in the ratio of 1:5 were mixed 
using pestle mortar until a homogeneous mixture was obtained 
and passed through 250 µm sieve.40 The improvement in aque-
ous solubility of EDR with PM and NEF was investigated 
in simulated body fluids (SBFs) such as simulated gastric 
fluid (SGF) (pH 1.2), SIF (pH 6.8 and pH 7.4), and water as 
described previously and compared with the EDR.27
Determination of active content in solid dispersion
The NEF equivalent to 1 mg of EDR was dissolved in 1 mL 
of methanol. The solution was further analyzed by using 
previously developed HPLC method. The loading ability 
and loading efficiency were determined based on the weight 
ratio of EDR to SOL in NEF and the amount of EDR loaded 
in the NEF from the initial value used for the preparation, 
respectively.41
investigating drug–polymer interaction 
with advanced characterization
Differential scanning calorimetry (Dsc) study
DSC analysis was carried out by using Discovery DSC 
(Model 2920; TA Instruments, New Castle, DE, USA). DSC 
was performed for the samples including EDR, SOL, PM, 
and NEF. The samples (2–4 mg) were taken in the aluminum 
open crucible, and an empty crucible was used as blank. 
Thermograms of each sample were recorded at the heating 
rate of 10°C/min, in the temperature range of 40°C–250°C 
under the flow (50 mL/min) of nitrogen gas.31,39
X-ray diffraction (XrD) study
XRD patterns were recorded for the samples including 
EDR, SOL, PM, and NEF to study the solid characteristics. 





The XRD instrument (PANalytical, Empyrean X-ray dif-
fractometer) was used, and diffractograms were taken by 
using CuKα radiation (λ=1.5418 Å), 40 kV voltage, and 
40 mA current. The scanning rate was 2° per minute in the 
2θ of 2°–50°.31,39
scanning electron microscopy (seM) study
Surface morphology was studied by using an instrument, 
Zeiss Microscopy Merlin with GEMINI II column. SEM 
study was carried out for the samples including EDR, SOL, 
and NEF. Each sample was mounted on the double-sided 
adhesive tape. The photomicrographs were obtained at 
the voltage of 0.7 kV and examined at the magnification 
of 2,000×.31,39
Fourier transform infrared (FTir) spectroscopy study
FTIR spectroscopy was carried out using a conventional 
potassium bromide (KBr) pellet method and a PerkinElmer 
Spectrum 400 spectrometer. The study was performed for 
the samples including native EDR, SOL, PM, and NEF. 
Briefly, 2–4 mg of samples were mixed with 100–150 mg 
of KBr and made pellet using the pressure of 8 tonnes for 
10–15 s. The KBr pellet was placed in the sample holder. 
FTIR spectra were obtained between 400 and 4,000 cm−1 at 
the scanning rate of 2 cm−1.38
1h nuclear magnetic resonance (nMr) study
Bruker AVANCE III 500 MHz was used to record the 1H 
NMR spectra at the frequency of 500 MHz. The samples 
including EDR and NEF were prepared by dissolving in 
DMSO-d
3
 followed by transferring to thin 5 mm diameter 
tubes prior to measurement. The data analysis was performed 
using the Topspin 3.2 software.42
assessment of self-nanomicellizing 
properties of neF
Preparation of eDr-loaded micelles solution of neF
An accurate quantity of NEF (equivalent to 15 mg EDR) 
was dispersed in 10 mL of water and kept on the mag-
netic stirrer for stirring at 500 rpm up to 3 h. The resultant 
mixture was then filtered through 0.45 µm PVDF filter to 
get the homogeneous micellar solution and to remove the 
unloaded EDR.43
characterization of eDr-loaded micelles
The Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) 
was used to measure the particle size, polydispersity index 
(PDI), and zeta potential of the above prepared micellar 
solution based on the principle of photon correlation spectros-
copy. In addition, a Philips CM 100 Transmission Electron 
Microscope fitted with an SIS MegaView II CCD camera 
was used to determine morphological characteristics using 
transmission electron microscopy (TEM) analysis. Briefly, 
a tiny drop of micellar solution was kept on the copper grid 
followed by drying overnight and analyzed by the Image 
Analysis Software.
To determine drug loading and entrapment efficiency of 
micelles, EDR-loaded micellar solution was freeze-dried. 
Before freeze drying, the micellar solution was kept in a deep 
freezer maintained at −80°C for 24 h (MDF-U74V-PE; Pana-
sonic Healthcare Co., Ltd., Tokyo, Japan). The sample was 
then freeze-dried using lyophilizer (Labconco Corporation, 
Kansas City, MO, USA) at −44°C and 8×10−3 M bar for 36 h. 
The freeze-dried powder was further dissolved in methanol 
and analyzed by using previously developed HPLC method. 
The percentage of drug loading and percentage of entrapment 
efficiency were determined based on the weight ratio of EDR 
in micelles to total mass of micelles and the amount of EDR 
loaded in micelles from the initial mass of EDR used for the 
preparation of micelles, respectively.43
stability study
Stability study of EDR-loaded micelles was performed at 
various stability conditions including hydrolytic, thermal, 
and photolytic, up to 24 h as described previously.27 For 
hydrolytic condition, 2 mL of each solution (pH 2–10) 
was filled in the glass bottle and covered with aluminum 
foil to protect from light and kept at 25°C. The solution 
was kept under various conditions, which included 4°C, 
25°C/60% relative humidity (RH), and 40°C/75% RH for 
determining the stability against temperature. The EDR 
micellar solution was kept in the KBF ICH 720 (E2) – a 
constant climate chamber as per the International Council 
for Harmonization (ICH) guideline to determine the stability 
when exposed to light. The samples were taken out at prede-
termined time points and analyzed with HPLC.27
Physical stability study of neF as per ich 
guideline
The stability study of NEF was carried out by evaluating 
the percentage of drug content and aqueous solubility up 
to 8 weeks as per ICH guideline.27 The stability conditions 
include 4°C, 25°C/60% RH, and 40°C/75% RH. The NEF 
was filled in the glass vials, sealed, and stored in the stability 
chamber after covering with aluminum foil. The aliquots 
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were collected at predetermined time intervals and analyzed 
by HPLC method.
in vitro permeation and metabolism 
study of neF
In vitro permeation and metabolism study were carried out 
as per our previous study.27,31 Male Wister rats (180–200 g) 
were used to prepare everted sacs of gut for the assay. Each 
sac was filled with 2 mL of Tyrode’s solution having the 
EDR concentration of 287.02 µmol with or without borneol 
(1.30 mmol) and NEF (equivalent to EDR concentration 
287.02 µmol). The amount of EDR and EDR glucuronide 
(EDR-G) metabolites and the rate of permeation were deter-
mined and compared.
in vitro dissolution study
A dissolution study was performed for EDR and NEF by 
using United States Pharmacopeia (USP) type II (paddle) 
apparatus at 37°C and 50 rpm.34 EDR and NEF were placed 
in the dissolution flask containing 900 mL of dissolution 
media including SGF (pH 1.2) and SIF (pH 6.8). The 
samples were collected and replaced with an equal volume 
of the dissolution media at different time points 5, 15, 30, 
45, 60, 90, and 120 min. Each sample was further filtered 
through 0.45 µm PVDF syringe filters followed by dilution if 
required with mobile phase. The amount of the drug released 
at each time point was determined by previously developed 
HPLC method. SNMSD could be categorized under con-
trolled release formulation; the use of various mathematical 
models in describing drug release from solid dispersion 
including zero-order, first-order, Higuchi, Hixson–Crowell, 
and Korsmeyer–Peppas models was well recognized and 
reported.44–47 Specifically, a solid dispersion using SOL 
could improve dissolution due to solid-state transformation 
as well as micellization. The use of zero-order, first-order, 
Higuchi, Hixson–Crowell, and Korsmeyer–Peppas models 
has been successfully described for drug release from SOL-
based solid dispersion.47,48 Thus, the results obtained from the 
HPLC analysis were fitted into the different release kinetic 
models including first order, zero order, Hixson–Crowell, 
Higuchi matrix, and Korsmeyer–Peppas to determine the 
release kinetic. In addition, the release profile of native EDR 
and NEF was compared by calculating the dissimilarity (f1) 
and similarity (f2) factors to understand the impact of pH on 
release. The formulas to determine the best suitable release 
kinetic model and dissimilarity and similarity factors are 
mentioned in Table S1. Dissolution profiles are considered 
to be similar if the f1 and f2 values are ,15 and 50–100, 
respectively.
in vivo pharmacokinetic study
The animal study was carried out as per the previous report 
using the male Sprague Dawley rats (300±25 g) and was 
approved by the Animal Ethics Committee of the University 
of South Australia under South Australian Animal Welfare 
Act 1985.27 The dose-dependent pharmacokinetic study of 
NEF was conducted and compared with the EDR suspension 
prepared using 0.5% sodium carboxymethylcellulose. Based 
on our previous publications, the standard deviation (SD) 
was determined within the 20% of mean. Thus, the sample 
size n=6 was calculated for the detection of difference of 
25% between groups at the β level of 80% and the α level 
of 5%.27,31 Four groups of rats (n=6) were orally administered 
with the EDR suspension of 172 µM/kg and NEF equivalent 
to 46, 138, and 414 µM/kg of EDR. The plasma samples have 
been collected at the predetermined time interval of 0, 5, 15, 
30, 45, 60, 90, 12, 180, 240, 300, 360, 420, and 480 min. 
EDR was extracted from the plasma by using the mixture of 
Mcllvaine buffer (pH 5.4) and dichloromethane-n-pentane 
(3:7, v/v) as mentioned in our study.27 EDR concentration in 
each sample was measured using the liquid chromatography-
tandem mass spectrometry method, and Phoenix WinNonlin 
software was used to calculate the pharmacokinetic param-
eters.27 The study has been conducted for 8 h as the level of 
EDR was below detection limit after 8 h.
statistical analysis
Mean and SD were used to present all values. The statistical 
analysis of data was conducted using GraphPad Prism 6. 
Data were evaluated for normal distribution first using 
Shapiro–Wilk test. Based on the results, further analysis 
was performed using Student’s t-test for two groups, or 
one-way or two-way analysis of variance (ANOVA) for 
multiple groups. P-values ,0.05 were considered statisti-
cally significant.
Results and discussion
Development of formulation and 
optimization of neF
Poor solubility, dissolution, metabolism, and permeability 
are determined as challenges that resulted in poor oral BA 
of EDR.27 The SNMED strategy is the combination of solid 
dispersion and nanomicelles strategies, which are the part of 
the most exciting area to curb the issues that restrict drug’s 
absorption and displayed a potential for overall improvement 





in the BA. It is the system where drug molecule disperses 
in the polymeric carrier similar to solid dispersion-based 
formulation.49,50 The role of polymeric carrier is critical for 
drug solubilization, stabilization, improving dissolution, 
permeability, and absorption.34,51 Therefore, miscibility 
study was used to finalize the most suitable polymer for the 
development of NEF. Furthermore, the ratio of drug to car-
rier was chosen based on the kinetic solubility study. Also, 
the solubility of optimized NEF was compared with a PM 
of EDR and carrier with the similar amount used in NEF to 
evaluate the impact of the presence of polymeric carrier on 
the solubility profile of EDR.
selection of suitable carrier for the development 
of neF
A number of carriers were shortlisted from the literature 
based on their potential to overcome the hurdles in the 
development of a novel oral delivery system such as PVP 
K30, SOL, PEG 4000, poloxamer 188, and poloxamer 
407.38,39 In addition to abovementioned polymers, HP-β-CD 
was considered as a control based on its proven ability to 
improve the solubility and dissolution of EDR.52 The reported 
aqueous solubility of EDR was 1.85±0.15 mg/mL.27 The 
increment in the aqueous solubility of EDR was observed 
with increasing the percentage of polymer content (w/v). The 
regression coefficient (R2) values for PVP K30, SOL, PEG 
4000, HP-β-CD, poloxamer 188, and poloxamer 407 are 
0.997, 0.994, 0.951, 0.971, 0.917, and 0.989, respectively. 
The polymers such as PVP K30 and SOL suggested the best 
linear relationship in the enhancement of solubility with the 
polymer concentration compared to other polymers. Also, 
10% SOL showed 4.67-fold improvement in the aqueous 
solubility of EDR, whereas with the same concentration 
of HP-β-CD, PVP K30, PEG 4000, poloxamer 188, and 
poloxamer 407 presented 3.49-, 2.22-, 1.73-, 1.74-, and 2.14-
fold enhancement, respectively (Figure 1A). The solubility 
enhancement of EDR with SOL is statistically significantly 
greater than HP-β-CD, which justified the selection of SOL 
for the development of NEF.
There are a number of reasons based on the literature and 
experiments which might explain the superior performance 
of SOL over another carrier including hydrogen bonding 
interactions with EDR as it has two hydrogen donor and two 
acceptor groups while EDR has two hydrogen donor groups 
and ability to form solid solution with EDR, which makes 
EDR available in a dissolved state,53 can act as a precipita-
tion inhibitor, keeps the supersaturated condition for at least 
24 h based on the results of kinetic solubility study,39 and 
can favor micellar solubilization.39
Kinetic solubility study
The ratio of EDR to SOL was optimized based on the kinetic 
solubility study. The maximum and equilibrium solubility 
and time for precipitation were determined for each ratio. 
The SD showing highest solubility without precipitation was 
considered for the development of NEF.39 The crystalline 
EDR displayed equilibrium aqueous solubility and maxi-
mum solubility (1.85±0.15 mg/mL27 and 2.29±0.32 mg/mL, 
respectively). Additionally, the precipitation was seen after 
30 min, which could be a reason for the difference in the 
values of maximum solubility and equilibrium solubility. 
With a good agreement to miscibility study, the solubility of 
EDR was significantly enhanced with the increasing concen-
tration of SOL in up to 1:5 EDR-to-SOL ratio. Approximately 
5- and 11-fold improvements in aqueous solubility were 
observed with SDs having 1:1 and 1:2.5 ratios, while the 
SD with 1:5 ratio showed the highest solubility enhancement 
(17.5-fold) compared to all ratios used for the optimization 
study (Figure 1B). Interestingly, lower solubility was detected 
with 1:7.5, 1:10, 1:12.5, and 1:15 ratios compared to 1:5 ratio 
but significantly higher in comparison with crystalline EDR 
with ~11-, 9-, 6.6-, and 6.5-fold, respectively. The decreasing 
solubility after certain drug-to-polymer ratio could be due 
to reaching beyond supersaturation stage, which was also 
observed in the previous study with SOL, PEG 4000, and 
PVP K30 polymers.38 No precipitation was noticed with all 
ratios, suggesting the critical role of SOL as a precipitation 
inhibitor by maintaining supersaturation condition for the 
desired period. The binary solid dispersion system of EDR 
and SOL with 1:5 ratio was considered as an NEF.
characterization of neF
comparison of solubility of neF with unformulated 
eDr and PM
There was a significant enhancement in aqueous solubility 
of EDR observed with PM (3.88-fold) and NEF (17.53-fold) 
(Figure 1C). The NEF displayed 4.51-fold greater solubility 
improvement compared to PM. Partial amorphization 
could be a potential reason for the low solubility of EDR 
with PM compared to NEF.54 The solubility of EDR in 
SGF (pH 1.2) was significantly greater (4.46-fold), while 
SIF (pH 6.8 and 7.4) showed an insignificant difference 
compared to solubility in water. The PM and NEF showed 
significant enhancement in the solubility of EDR in all SBFs. 
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The exceptional performance of NEF was further investigated 
with advanced characterization study of NEF.
Determination of active content in solid dispersion
NEF is an amorphous solid dispersion, which can be defined 
as a molecular mixture of poorly water-soluble drugs and 
hydrophilic carriers.55 The manufacturing process of solid 
dispersion should ideally allow entire amount of EDR to 
be mixed with SOL to form NEF. The drug loading and 
efficiency as applied to other formulations such as nano-
particles will be not applied with solid dispersion-based 
formulations. To determine the proportion of EDR in NEF 
to understand the loss of EDR in manufacturing, we have 
used methanol technique. The proportion of EDR in NEF 
was 16.52%±0.16% (w/w), which is 99.03%±0.42% of the 
initial amount. No significant loss of EDR was observed 
during the manufacturing by SE technique.
investigating drug–polymer interaction 
with advanced characterization
Change in solid-state characteristics from crystalline to 
amorphous, hydrogen bonding interaction, and micellization 
are perhaps potential reasons for the dramatic improvement 
in EDR aqueous solubility with NEF.31 To evaluate our 
hypothesis, DSC, XRD, and SEM studies were conducted to 
determine if any change happened in solid-state characteris-
tics of EDR and SOL when compared to optimized NEF.31,39 
Also, the possibility of hydrogen bonding between EDR and 
SOL was assessed from FTIR and 1H NMR analyses.41 The 
micellization property of NEF was studied by evaluating its 
β
Figure 1 Formulation development and optimization of neF.
Notes: Miscibility study of eDr with various polymers (A), optimization of eDr-to-sOl ratio for the development of neF (B), and solubility assessment of eDr, PM, and 
neF in sgF (ph 1.2) and siF (ph 6.8 and 7.4) (C) (mean ± sD, n=3).
Abbreviations: eDr, edaravone; hP-β-cD, hydroxypropyl-β-cyclodextrin; neF, novel eDr formulation; PM, physical mixture; Peg 4000, polyethylene glycol 4000; 
PVP K30, polyvinylpyrrolidone K 30; sD, standard deviation; sOl, soluplus®; SGF, simulated gastric fluid; SIF, simulated intestine fluid.





aqueous solution for the parameters such as particle size, zeta 
potential, and PDI by zetasizer and TEM analyses.56
Dsc study
The thermal behavior of EDR, SOL, PM, and NEF is shown 
in Figure 2A. The characteristic melting endothermic peak at 
128.39°C was recorded with pure EDR, which confirmed the 
crystalline nature of EDR used in the preparation of devel-
oping NEF. SOL did not display any thermal event due to 
amorphous nature of the polymer reported in the literature.57 
Less intense endothermic peak was seen in the case of PM, 
which might be due to the partial amorphization because of 
the force used in mixing during preparation with mortar and 
pestle or dilution effect of SOL. The disappearance of the 
sharp melting endothermal peak of EDR in the thermogram 
of NEF revealed the complete alteration of the solid state of 
EDR from crystalline to amorphous.
XrD study
The solid-state characteristic of NEF was further confirmed 
with XRD study by comparing diffractograms of pure EDR, 
SOL, PM, and NEF. Pure EDR showed sharp characteris-
tics peaks at 11.2, 13.7, 14.7, 20.1, and 21.4 2θ assuring its 
crystalline nature, whereas amorphous nature of SOL was 
confirmed from its diffractogram without any characteristic 
peaks (Figure 2B). The decrease in the intensity of all char-
acteristic peaks of pure EDR in the diffractogram of PM 
verified the results of partial conversion to amorphous or dilu-
tion effect of SOL from DSC study (Figure 2B). However, 
diffractogram of NEF exhibited apparently absent of all peaks 
of pure EDR, which indicated complete amorphization of 
EDR in NEF (Figure 2B). SOL has been previously shown 
to have the unique capability of interacting with the drug 
molecules via H-bonds as it has two each of hydrogen donor 








self-nanomicellizing solid dispersion of edaravone
the EDR crystal surfaces, especially with the 2θ values of 
11.2, 13.7, 14.7, 20.1, and 21.4° and disruption of the crystal 
lattice and order.59 The results of XRD analysis show a good 
agreement with the DSC study.
seM study
The SEM analysis was performed to determine the surface 
micrographs of pure EDR, SOL, and NEF. The large agglom-
erate particles with ordered size and shape were observed in 
the micrograph of pure EDR, which indicated its crystalline 
nature (Figure 2C). Moreover, irregular-shaped particles 
were seen in the micrograph of SOL revealing its amorphous 
nature (Figure 2D). Furthermore, the micrograph of NEF 
demonstrated particles with relatively rough surface and dis-
ordered shape, which specified the amorphous nature of EDR 
in NEF without any traces of crystalline EDR (Figure 2E). 
The surface characteristics of NEF facilitate the quick and 
efficient dissolution of NEF upon contact with aqueous 
fluids.60 The confirmation of complete amorphization of EDR 
in NEF from SEM results is consistent with the results of 
DSC and XRD analyses.
FTir and 1h nMr study
The hydrogen bond interaction could be possible between EDR 
and SOL due to the presence of hydrogen donor and acceptor 
chemical groups in their chemical structure.27,43 Therefore, the 
interaction between EDR and SOL was investigated using 
FTIR and 1H NMR. FTIR spectra of pure EDR, SOL, PM, 
and NEF are displayed in Figure 3A–D, respectively. Pure 
EDR (Figure S1) showed peaks at 3,200–3,600 cm−1 corre-
sponding to N−H and O−H stretching, 1,580–1,627 cm−1 in 
regard to C=N stretching, and 2,850–3,100 for aliphatic and 
aromatic C−H stretching. SOL displayed peaks representing 
O−H stretching and aliphatic C−H stretching, which were 
similar to EDR. The stretching corresponding to carbonyl 
group was additionally observed at 1,670–1,820 cm−1 in SOL 
spectra. The shifting or broadening of peaks between 3,200 
and 3,600 cm−1 was witnessed in FTIR spectra of NEF, which 
indicated the involvement of chemical groups present in EDR 
and SOL such as N−H and O−H in hydrogen bonding. Addi-
tionally, a similar observation was seen between 1,670 and 
1,820 cm−1 that confirm the participation of carbonyl group 
of SOL in hydrogen bonding. Shifting of chemical shifts was 
Figure 2 Dsc, XrD, and seM characterization study.
Notes: Dsc thermographs (A) and X-ray diffractograms (B) of eDr, sOl, PM, and neF, seM photomicrographs of eDr (C), sOl (D), and neF (E). (A) and (B) Data from 
Parikh et al.27,31 (C) reprinted from Drug Deliv, 24(1), Parikh a, Kathawala K, Tan cc, garg s, Zhou XF, lipid-based nanosystem of edaravone: development, optimization, 
characterization and in vitro/in vivo evaluation, 962–978, copyright © 2017, with permission from elsevier. The results of Dsc, XrD, and seM of sOl were used as a control 
for other projects.
Abbreviations: eDr, edaravone; Dsc, differential scanning calorimetry; neF, novel eDr formulation; PM, physical mixture; seM, scanning electron microscopy; 
sOl, soluplus®; XrD, X-ray diffraction.





Figure 3 FTir and nMr characterization study.
Notes: FTir spectra of eDr (A), sOl (B), PM (C), and neF (D) and 1h nMr spectra of eDr (E) and neF (F). The result of FTir of sOl was used as a control for other 
projects.
Abbreviations: eDr, edaravone; FTir, Fourier transform infrared; neF, novel eDr formulation; nMr, nuclear magnetic resonance; PM, physical mixture; sOl, soluplus®.
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also observed in the results of 1H NMR of NEF compared to 
pure EDR, which could be considered as a proof of hydrogen 
bonding interaction between the drugs and polymer as per 
the previous publication (Figure 3E and F and Table S2).41 
SOL has two each of hydrogen donor and acceptor groups 
while EDR has two hydrogen donor groups. As the optimized 
ratio of EDR to SOL for the development of NEF is 1:5, five 
times more SOL molecules are present in the NEF, which 
could facilitate six hydrogen bonding interactions. From the 
results of FTIR and NMR studies, the strong hydrogen bond-
ing interaction between EDR and SOL was confirmed, which 
could interact with the EDR crystal surfaces, especially with 
the 2θ values of 11.2, 13.7, 14.7, 20.1, and 21.4 and disruption 
of the crystal lattice and order. The formation of hydrogen 
bond between drug and polymer in preparation could restrict 
the solid-state change from amorphous to crystalline during 
the storage and provide physical stability to the formula-
tion.61 Similar results have been reported previously in solid 
dispersion-based preparations.41,60
assessment of self-nanomicellizing 
properties of neF
SOL, a graft copolymer of poly(vinyl caprolactam)–
poly(vinyl acetate)–poly(ethylene glycol), could form 
micelles over the concentration of 7.6 mg/L.56 The micellar 
system of SOL showed dramatic improvement in oral BA 
of drugs such as quercetin56 and cyclosporine A43 and the 
therapeutic efficacy of drugs such as doxorubicin,62 α-lipoic 
acid,63 and carvedilol.64 Thus, the self-nanomicellizing prop-
erties of NEF after dissolving NEF in aqueous media were 
investigated. The particle size is the most critical parameter 
as ,100 nm could enhance cellular uptake of drugs and also 
facilitate the transport across the intestinal membrane by 
paracellular or transcellular routes.56 The average particle 
diameter of 73.46±3.15 nm, the PDI of 0.12±0.04, and the 
zeta potential of −4.98±1.56 mV were observed using zeta-
sizer. A TEM photograph of micelles of NEF revealed the 
spherical droplets with the good agreement of particle size 
measured by zetasizer (Figure 4A). Additionally, micellar 
formulation remained stable with and without 20-fold dilu-
tion with dissolution media such as SGF (pH 1.2) and SIF 
(pH 6.8) after 24 h. The narrow size distribution, which 
prevents particle growth due to Ostwald ripening, could 
also justify the good stability of micelles in dissolution 
media.65 The percentage of drug loading and percentage of 
entrapment efficiency of micelles were 0.143 and 95.46, 
respectively.
Moreover, the uniform dispersion of NEF in various 
aqueous buffer systems from pH 2 to 8, SBF, and water 
confirmed nearly complete encapsulation of EDR in micelles. 
The complete encapsulation could provide protection to 
EDR against the degradation or metabolism in the presence 
of gastrointestinal contents.66 Thus, the stability of EDR in 
micelles at different pH and temperatures, in the presence 
of light, and in SBF such as SGF (pH 1.2) and SIF (pH 6.8) 
was examined for 24 h. There was no significant degrada-
tion (,3% degradation) of EDR that was detected in all 
conditions, while crude EDR showed dramatic degradation 
at alkaline conditions (pH 8–10).27 These results confirmed 
the complete amorphization, strong hydrogen bonding 
interaction, and micellization, which made NEF an excellent 




























Figure 4 TeM characterization study and stability study of neF.
Note: TeM image of micellar solution of neF (A) and stability assessment of neF as per ich guideline (B) (mean ± sD, n=3).
Abbreviations: eDr, edaravone; ich, international council for harmonization; neF, novel eDr formulation; sD, standard deviation; TeM, transmission electron microscopy.





Physical stability study of neF as per ich 
guideline
No significant difference in the percentage of drug con-
tent and the aqueous solubility of EDR was witnessed 
(Figure 4B). Therefore, it might be stored at #40°C for at 
least 8 weeks. The strong hydrogen bond interaction between 
EDR and SOL could favor the physical stability of EDR in 
NEF and prevent the conversion of solid state from amor-
phous to crystalline.61
in vitro metabolism and permeation study
EDR was previously recognized as a substrate of UGT 
enzymes.26 Thus, it rapidly undergoes extensive metabolism, 
which results in poor oral BA.27,31 The inhibition of glucuroni-
dation is the critical requirement in improving the oral BA 
of EDR. Borneol is known for its inhibitory effect on 
glucuronidation and considered as a positive control in 
investigating the inhibitory effect of excipients on glucuroni-
dation.67 Thus, similar to our previous studies, borneol was 
considered as a positive control in the current study.27,31
The novel oral delivery system and LNS of EDR showed 
5.71- and 10.79-fold improvements in the oral BA of EDR, 
respectively, due to the inhibitory effect of surfactants on 
glucuronidation and the Pgp efflux of EDR during metabo-
lism and permeability.27,31 Based on such information, the 
impact of SOL on the glucuronidation of EDR was studied 
in rat liver microsomes. The significant inhibitory effect of 
SOL (45.64%) compared to borneol (37.56%) was observed 
(Figure 5A). The potential of SOL-based NEF was further 
tested on the permeability and metabolism of EDR during 
permeation across the small intestine using the everted 
intestine sac technique. The inhibitory effect of SOL was 
also witnessed as NEF displayed 2.73-fold greater transfer 
amount of EDR compared to crude EDR and statistically 
significant compared to borneol (Figure 5B). Additionally, 
NEF presented 41.67 and 15% less amount of EDR-G on the 
serosal side compared to crude EDR and borneol, respectively 
(Figure 5C). Moreover, it presented 59.9% and 44.2% fewer 
molar ratio of EDR-G to EDR compared to crude EDR and 
borneol, respectively, which indicated a statistically signifi-
cant effect of SOL present on the NEF glucuronidation of 
EDR (Figure 5D). There were 2.96-fold higher transfer rate of 
EDR from NEF and 2.65-fold greater with borneol compared 
to crude EDR (Figure 5E). The inhibitory effect of SOL on 
Pgp efflux and ,100 nm of micelles generated from NEF 
could also enhance the permeability of EDR across the small 
intestine.56 The results confirmed the significant improvement 
in the metabolism and permeability profile of EDR with NEF 
due to the inhibitory effect of SOL on glucuronidation.
in vitro drug dissolution
The result of dissolution study of EDR and NEF is shown 
in Figure 6A. EDR showed 100% release within 15 min in 
SGF compared to 85% release in 120 min in SIF, which 
indicated pH-dependent release. It was further examined by 
comparing the dissolution profiles using f1 and f2 factors. 
The determined f2 value (similarity factor) and f1 value 
(dissimilarity factor) are 14 and 26, respectively, which 
confirmed the impact of pH of the media on EDR release. 
As per our previous report, EDR exhibited significantly 
higher pH-dependent solubility in SGF (8.26±1.42 mg/mL) 
than in SIF (1.89±0.51 mg/mL).31 The difference in dissolu-
tion results of crude EDR in SGF and SIF could be based 
on solubility data. Moreover, crude EDR followed Hixson–
Crowell and Korsmeyer–Peppas release kinetic models in 
SGF and SIF, respectively (Table 1). Additionally, in SIF, it 
followed an anomalous transport (non-Fickian) mechanism, 
which could be controlled by factors other than diffusion. 
The sedimentation and wetting of the EDR at interface could 
control the release of EDR in SIF.
The dissolution of NEF in SGF and SIF was 100% within 
15 and 30 min, respectively. There was a significant improve-
ment in the dissolution of NEF detected in SIF compared 
to crude EDR, whereas no dramatic change was witnessed 
between the dissolution profile of crude EDR and NEF in 
SGF except at 5 min. The amorphization, hydrogen bond-
ing interaction, and micellization could play a vital role in 
the improvement of dissolution behavior of EDR from NEF 
compared to crude EDR. Additionally, the f2 (65) and f1 (3) 
values confirmed the similar dissolution profiles of EDR in 
SGF and SIF, which suggested the minimum impact of pH 
on EDR release from NES. Moreover, the first-order release 
kinetic model was best fitted with the dissolution profiles of 
NEF. Thus, the rate of EDR release depends on the amount 
of EDR retained in NEF.68
EDR exhibited pH-dependent solubility in SGF (8.26±1.42 
mg/mL) and SIF (1.89±0.51 mg/mL), respectively.31 We 
have used 900 mL of dissolution media including SGF 
(pH 1.2) and SIF (pH 6.8) in the dissolution study. The 
fast release of EDR and EDR from NEF could be due to 
sufficient solubility and the large amount of dissolution 
media. Moreover, NEF is the amorphous solid dispersion, 
which can be defined as molecular mixture of EDR and 
SOL. Based on DSC and XRD results, there was no sig-
nificant amount of free EDR present in NEF. Moreover, 
during the process of micelles’ formation after dispersing 
NEF into dissolution media, EDR can be either encapsu-
lated in micelles or remained in unloaded form. Based on 
the results of drug loading and entrapment efficiency of 




self-nanomicellizing solid dispersion of edaravone
micelles, ~96% of EDR was found encapsulated in micelles. 
Thus, there should be a nonsignificant contribution from 
unloaded EDR in dissolution results. Additionally, a number 
of studies of solid dispersion-based formulation containing 
SOL showed the quick release of drugs (within 5 min).60,69,70 













































































































































Figure 5 The impact of sOl on permeability and metabolism of eDr.
Notes: inhibitory effect of sOl (1%) on eDr glucuronidation in a microsomal incubation assay (A), the amount (in percentage) of eDr (B) and eDr-g (C) in serosal 
side at predetermined time interval, molar ratio between eDr-g and eDr (D), and transfer rate of eDr in the serosal side (E) (mean ± sD, n=3). *P,0.05, **P,0.01, and 
***P,0.001. One-way anOVa and Tukey’s test or unpaired t-test (two tailed). Data from Parikh et al.27,31
Abbreviations: anOVa, analysis of variance; eDr, edaravone; eDr-g, eDr glucuronide; neF, novel eDr formulation; sD, standard deviation; sOl, soluplus®.
solutions, which makes the drug available in a dissolved 
state in quick time, resulting in an improved BA, once in the 
body. Moreover, SOL is hydrophilic in nature resulting in 
a better wettability of the drug. Furthermore, micellization 
is another mechanism that could contribute to the quick 
release of drug.39





in vivo pharmacokinetic study
The developed formulation in part I of the study would 
undergo the assessment of dose-dependent therapeutic 
effect against the Alzheimer’s disease in part II of the study. 
Thus, three different doses of NEF were considered for the 
pharmacokinetic study. The plasma concentration against 
time, pharmacokinetic parameters, and statistical analysis of 
pharmacokinetic parameters are displayed in Figure 6B and 
Tables 2 and S3, respectively. A significant increase in C
max
 
was observed at all doses of NEF compared to EDR suspen-
sion, while NEF did not show any difference in T
max
. These 
results are consistent with the result of dissolution study as 
NEF displayed quick release in both media similar to EDR 
suspension release in SGF. Also, NEF showed significantly 
longer t
1/2
 compared to EDR suspension, which could be 
due to the inhibitory effect of SOL on EDR glucuronidation. 
No significant difference in t
1/2
 value between the NEF groups 
with different doses was observed. Moreover, NEF exhibited 
dramatic increment in AUC
0–t
 and 10.24- (46 µM/kg), 16.08- 
(138 µM/kg), and 14.78- (414 µM/kg) fold enhancement 
in relative BA compared to EDR suspension. There was a 
significant difference in BA noticed between the groups of 
NEF with doses 46–138 and 414 µM/kg. EDR displays high 
protein binding (91.0%–91.9%), and it is possible that at the 
higher doses, protein-binding sites are saturated so that EDR 
remains free and available for metabolism and excretion.71,72 
The similar dose-dependent absorption via intraperitoneal 
route was also reported.73
The solubilizing amount of EDR in the vehicle used 
for pharmacokinetic study might significantly affect the 
outcome. Thus, determination of solubilized EDR in a total 
of 1.5 mL of vehicle used for oral administration in rats 
was performed. The dissolved part of EDR in the supplied 
vehicle was 31 and 100% with EDR suspension and NEF, 
respectively, for all doses. The presence of solubilized EDR 
in greater amount could be one of the reasons for significant 
improvement in oral BA.27 Moreover, with regard to disso-
lution results, both NEF and EDR showed fast dissolution 
(100%) within 15 min in the 900 mL of dissolution media. 
The reported fluid content in the gastrointestinal tract of the 
fasted rat is 3.2±1.8 mL.74 Therefore, EDR could precipitate 
in the rat stomach, even though it exhibits an exceptional 
Table 1 results of the release kinetics of eDr and neF in sgF and siF, respectively
Formulation Medium First order Zero order Hixson–Crowell Higuchi matrix Korsmeyer–Peppas
eDr sgF 0.834 0.6077 0.9216 0.8501 0.8636
siF 0.9609 0.7947 0.9718 0.97 0.9895
neF sgF 0.9982 0.6988 0.9212 0.9061 0.9171
siF 0.9862 0.5925 0.8807 0.8514 0.9078
Abbreviations: EDR, edaravone; NEF, novel EDR formulation; SGF, simulated gastric fluid; SIF, simulated intestine fluid.
Figure 6 in vitro dissolution study and in vivo oral bioavailability study of neF.
Notes: in vitro dissolution study of eDr and neF in sgF and siF (A) and plasma profile vs time curve for the EDR suspension and NEF (46, 138, and 414 µmol/kg) in sprague 
Dawley rats after oral administrations (B) (mean ± sD, n=6). Data from Parikh et al.27,31
Abbreviations: EDR, edaravone; NEF, novel EDR formulation; SD, standard deviation; SGF, simulated gastric fluid; SIF, simulated intestine fluid.
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dissolution profile in SGF. Similar results were observed in 
the kinetic solubility study where precipitation of EDR was 
noticed after 30 min in the absence of SOL. SOL is well rec-
ognized with its characteristic as a precipitation inhibitor by 
maintaining supersaturation. Thus, NEF could perform better 
in terms of in vivo dissolution. Moreover, we have shown 
that NEF displayed a 2.4-fold decrease in the glucuronida-
tion of EDR and a 2.73-fold greater transfer amount of 
EDR across the small intestine compared to nonformulated 
EDR. The inhibitory effect of SOL on glucuronidation, 
Pgp efflux, and ,100 nm of micelles generated from NEF 
could also enhance the metabolism and permeability of EDR 
across the small intestine. Also, improvement in dissolution, 
metabolism, and permeability profile could have played 
a vital role in the exceptional performance of NEF in the 
pharmacokinetic study compared to EDR suspension as per 
our previous reports.27,31
Conclusion
The poor oral BA of EDR due to poor aqueous solubility, 
dissolution, and permeability could hamper its optimum 
therapeutic use. To improve its BA, EDR-loaded NEF was 
developed using the SNMSD-based strategy. The impact on 
physicochemical characteristics of EDR, such as aqueous 
solubility, stability, and dissolution, as well as metabolism 
and permeability, was assessed. SOL as a polymer was 
selected based on its potential for improving solubility and 
stability. The optimized formulation, NEF, showed 17.5-fold 
improvement in SGFs. The mechanism of improvement of 
solubility and stability was extensively studied, and amor-
phization, hydrogen bonding interaction, and micellization 
were determined as significant contributors. Moreover, NEF 
showed better performance in in vitro metabolism and intesti-
nal permeability study compared to crude EDR. Furthermore, 
oral pharmacokinetic studies in rats showed that NEF was 
~16-fold bioavailable compared to unformulated EDR. The 
exceptional enhancement of oral BA of NEF compared to 
EDR suspension could be due to an improvement in solubil-
ity, dissolution, and permeability. Our studies proved that the 
developed NEF is a promising candidate for further study in 
oxidative stress-associated diseases.
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Table S1 Mathematical models used to describe drug dissolution curves
Equation Model Description
Qt = ln Q0 + K1t












Qt: amount of drug dissolved in time t, Q0: initial amount 
of drug in the solution, t: time, Q∞: amount of drug 
dissolved in time ∞, and K1, K0, Kc, Kh, and KK are the 
rate constants for first order, zero order, Hixson–


















Dissimilarity factor (f1) n: sampling number, Rj and Tj: percentage dissolved of the 
reference and test products at each time point j



























Figure S1 structure of eDr (3-methyl-1-phenyl-2-pyrazolin-5-one).
Abbreviation: eDr, edaravone.
Table S2 change in the position of chemical shifts of eDr and neF in 1h nMr spectroscopy







Abbreviations: eDr, edaravone; neF, novel eDr formulation; nMr, nuclear magnetic resonance.
Table S3 statistic analysis of the pharmacokinetic parameters
Group P-value for t1/2 P-value for F0–t P-value for Tmax
eDr suspension (172 µM/kg) vs neF (46 µM/kg) 0.0252 ,0.0001 0.9979
eDr suspension (172 µM/kg) vs neF (138 µM/kg) 0.0005 ,0.0001 0.9958
eDr suspension (172 µM/kg) vs neF (414 µM/kg) ,0.0001 ,0.0001 0.9914
neF (46 µM/kg) vs neF (138 µM/kg) 0.3147 0.0076 .0.9999
neF (46 µM/kg) vs neF (414 µM/kg) 0.0714 0.0448 0.9995
neF (138 µM/kg) vs neF (414 µM/kg) 0.8305 0.8460 .0.9999
Notes: t1/2, half-life; Tmax, peak time.
Abbreviations: eDr, edaravone; neF, novel eDr formulation.
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